Efficacy and Safety of Rituximab for Systemic Lupus Erythematosus Treatment: a Meta-analysis

Overview

Journal Afr Health Sci

Date 2020 Nov 9

PMID 33163054

Citations 4

Authors

Shanshan Wu

Yanhai Wang

Jiaojiao Zhang

Bo Han

Baishan Wang

Wanli Gao

Ning Zhang

Cheng Zhang

Feng Yan

Zhijing Li

Affiliations

Soon will be listed here.

Abstract

Background: Given the inconsistency of previous studies and the newly emerging evidence, we decided to conduct a meta-analysis.

Methods: The meta-analysis included 2 randomized controlled trials and 13 observational studies 742 patients in total. Qualified studies were properly searched from databases . Data were analyzed by the RevMan 5.3 software. Results were demonstrated as WMD , SMD and RR with 95% CIs, I and P value.

Results: we observed that a remarkable increase of complement C3 in the rituximab group than placebo group (WMDfixed= 7.67mg/dL, 95%CIs=-0.16~15.50, I=0%, P=0.05). A significant increase of complement C4 was observed in the rituximab group than placebo group (WMDfixed=3.14mg/dL, 95%CIs=1.06~5.22, I=0%, P=0.003). Notably decreased peripheral CD19+B cells in rituximab group than placebo group (WMDfixed=-117.93n/µl, 95%CIs=-172.94~-62.91, I=0%, P<0.0001) in RCTs. Patients with severe or refractory SLE got more satisfactory efficacy results after receiving rituximab in observational studies, such as British Isles Lupus Assessment Group index score, SLE Disease Activity Index score, complement C3/C4, anti-dsDNA antibodies, peripheral CD19B cells and so on. Safety profiles were no difference between rituximab and placebo groups.

Conclusion: although the efficacy of rituximab is highly controversial for SLE, our study shows that rituximab presents a satisfying efficacy and safety for SLE.

Citing Articles

Therapeutic Antibodies in Medicine.

Sharma P, Joshi R, Pritchard R, Xu K, Eicher M Molecules. 2023; 28(18).

PMID: 37764213 PMC: 10535987. DOI: 10.3390/molecules28186438.

Ubiquitin D promotes the progression of rheumatoid arthritis via activation of the p38 MAPK pathway.

Chen H, Tao L, Liang J, Pan C, Wei H Mol Med Rep. 2023; 27(2).

PMID: 36660934 PMC: 9879075. DOI: 10.3892/mmr.2023.12940.

Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis.

Li K, Yu Y, Gao Y, Zhao F, Liang Z, Gao J Front Immunol. 2022; 13:859380.

PMID: 35444666 PMC: 9013779. DOI: 10.3389/fimmu.2022.859380.

Can we predict if patients with SLE will require more than one cycle of rituximab?.

Fernandez Gonzalez R, Abida R, Gisca E, Duarte L, Isenberg D Rheumatology (Oxford). 2021; 61(5):1892-1899.

PMID: 34240116 PMC: 9071578. DOI: 10.1093/rheumatology/keab527.

References

Catapano F, Chaudhry A, Jones R, Smith K, Jayne D . Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010; 25(11):3586-92. DOI: 10.1093/ndt/gfq256. View

Md Yusof M, Shaw D, El-Sherbiny Y, Dunn E, Rawstron A, Emery P . Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017; 76(11):1829-1836. PMC: 5705851. DOI: 10.1136/annrheumdis-2017-211191. View

DCruz D, Khamashta M, Hughes G . Systemic lupus erythematosus. Lancet. 2007; 369(9561):587-96. DOI: 10.1016/S0140-6736(07)60279-7. View

Reddy V, Jayne D, Close D, Isenberg D . B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther. 2013; 15 Suppl 1:S2. PMC: 3624107. DOI: 10.1186/ar3910. View

Plosker G, Figgitt D . Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003; 63(8):803-43. DOI: 10.2165/00003495-200363080-00005. View

Sfikakis P, Boletis J, Lionaki S, Vigklis V, Fragiadaki K, Iniotaki A . Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005; 52(2):501-13. DOI: 10.1002/art.20858. View

Vital E, Dass S, Buch M, Henshaw K, Pease C, Martin M . B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011; 63(10):3038-47. DOI: 10.1002/art.30466. View

Rovin B, Furie R, Latinis K, Looney R, Fervenza F, Sanchez-Guerrero J . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64(4):1215-26. DOI: 10.1002/art.34359. View

Leandro M, Cambridge G, Edwards J, Ehrenstein M, Isenberg D . B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005; 44(12):1542-5. DOI: 10.1093/rheumatology/kei080. View

10.

Li E, Tam L, Zhu T, Li M, Kwok C, Li T . Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. Rheumatology (Oxford). 2009; 48(8):892-8. DOI: 10.1093/rheumatology/kep124. View

11.

Wilczynski N, Haynes R . Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey. BMC Med. 2004; 2:23. PMC: 441418. DOI: 10.1186/1741-7015-2-23. View

12.

Taylor R, Lindorfer M . Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007; 3(2):86-95. DOI: 10.1038/ncprheum0424. View

13.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

14.

Cervera R, Khamashta M, Font J, Sebastiani G, Gil A, Lavilla P . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82(5):299-308. DOI: 10.1097/01.md.0000091181.93122.55. View

15.

Zhang J, Zhao Z, Hu X . Effect of Rituximab on Serum Levels of Anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis. Cell Biochem Biophys. 2014; 72(1):197-201. DOI: 10.1007/s12013-014-0437-z. View

16.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

17.

Andrade-Ortega L, Irazoque-Palazuelos F, Lopez-Villanueva R, Barragan-Navarro Y, Bourget-Pietrasanta F, Diaz-Ceballos M . [Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study]. Reumatol Clin. 2011; 6(5):250-5. DOI: 10.1016/j.reuma.2009.11.004. View

18.

Ramos-Casals M, Soto M, Cuadrado M, Khamashta M . Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009; 18(9):767-76. DOI: 10.1177/0961203309106174. View

19.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

20.

Ginsberg J, Chang B, Matarese R, GARELLA S . Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983; 309(25):1543-6. DOI: 10.1056/NEJM198312223092503. View